Sensitization to human leukocyte antigens in heart transplantation.

Jahanzeb Malik*

Department of Cardiovascular Research, Cardiovascular Analytics Group, Islamabad, Pakistan.

Introduction

Heart transplantation has emerged as a life-saving treatment for end-stage heart failure patients. However, the success of heart transplantation relies heavily on the compatibility between the donor and recipient. One critical aspect of compatibility is the presence of human leukocyte antigens (HLAs), which play a pivotal role in the immune response. Sensitization to HLAs can pose significant challenges in heart transplantation, impacting graft survival and patient outcomes. This article delves into the complexities of sensitization to HLAs in heart transplantation, exploring its causes, consequences, and potential solutions.Human Leukocyte Antigens, also known as HLA, are proteins found on the surface of most cells in the human body. They are critical for the immune system's ability to differentiate between self and non-self-cells. HLAs help the immune system identify and target foreign invaders, such as viruses and bacteria. In the context of heart transplantation, HLAs are a fundamental consideration because they are responsible for immune responses against the transplanted heart [1,2].

Sensitization to HLAs occurs when a recipient's immune system develops antibodies against specific HLA proteins. This sensitization can happen due to various reasons. Patients who have previously received organ transplants, blood transfusions, or even pregnancies are at a higher risk of sensitization. These events expose them to foreign HLAs, leading to the development of antibodies against these antigens. Receiving multiple blood transfusions before transplantation can increase the likelihood of sensitization. The transfused blood may contain HLAs that the recipient's immune system recognizes as foreign.During pregnancy, a woman may be exposed to the father's HLA antigens present in the fetus. This exposure can lead to the production of antibodies against these specific HLAs.Some viral infections, such as cytomegalovirus (CMV) and Epstein-Barr virus (EBV), can cause sensitization by triggering an immune response against HLAs [3,4].

Sensitized recipients are at a higher risk of acute antibody-mediated rejection (AMR), a severe form of rejection that can lead to graft failure. The antibodies produced against donor HLAs can attack the transplanted heart, causing damage. Sensitized patients often face longer waiting times for a suitable donor match. Finding a donor with HLAs that are not recognized by the recipient's antibodies can be challenging, delaying the transplant process .Sensitization is associated with decreased graft survival rates. The presence of antibodies against HLAs increases the likelihood of graft failure over time.Managing sensitized patients can be complex. Treatment options, such as desensitization therapies, are available but may not always be effective [5,6].

Efforts to address sensitization in heart transplantation have led to the development of various strategies and therapies. Pre-transplant crossmatching is crucial to identify compatible donors. This process involves mixing the recipient's serum with potential donor lymphocytes to detect any existing antibodies against the donor's HLAs.Desensitization protocols aim to reduce the levels of antibodies against HLAs in sensitized patients. These protocols may include plasmapheresis (removing antibodies from the blood), intravenous immunoglobulin (IVIG) therapy, and immunosuppressive medications [7,8].

In cases where a sensitized patient cannot find a compatible donor, paired exchange programs can be an option. These programs facilitate the exchange of donors between two incompatible pairs, increasing the chances of finding a suitable match.Advances in immunological testing have improved the ability to assess the compatibility between donors and recipients. Techniques like single antigen bead assays help identify specific antibodies and evaluate their strength .Some transplant centers maintain registries of sensitized patients, which can help match them with suitable donors and facilitate transplantation.Ongoing research aims to induce immune tolerance in sensitized recipients. These approaches seek to re-educate the immune system to accept the transplanted organ despite the presence of antibodies [9,10].

Conclusion

Sensitization to HLAs remains a significant challenge in heart transplantation, impacting both graft survival and patient outcomes. Understanding the causes and consequences of sensitization is crucial for transplant teams to develop effective strategies for sensitized patients. Advances in immunological testing, desensitization therapies and innovative strategies like paired exchange programs offer hope for sensitized individuals in need of a life-saving heart transplant. Continued research and collaboration among transplant centres are essential to improve the outcomes of sensitized patients and expand the pool of available donors.

Reference

1. Shah AC. Telemedicine in Pediatrics: Systematic Review of Randomized Controlled Trials. JMIR Pediatr Parent. 2021;4:e22696.

***Correspondence to:** Jahanzeb Malik**,** Department of Cardiovascular Research, Cardiovascular Analytics Group, Islamabad, Pakistan, E-mail: Jahanzeb@gmail.com

***Received:** 29-Nov-2023, Manuscript No. AACC-23-128829; **Editor assigned:** 01-Dec-2023, Pre QC No. AACC-23-128829(PQ); **Reviewed:** 16- Dec-2023, QC No. AACC-23-128829; **Revised:** 21-Dec-2023, Manuscript No. AACC-23-128829 (R), **Published:** 28-Dec-2023,DOI:10.35841/aacc-7.12.233*

***Citation:** Malik J. Sensitization to human leukocyte antigens in heart transplantation. Curr Trend Cardiol 2023;7(12):233*

2. Badawy SM. Digital Approaches to Remote Pediatric Health Care Delivery During the COVID-19 Pandemic: Existing Evidence and a Call for Further Research. JMIR Pediatr. Parent. 2020;3:e20049.

3. Alberts NM. Development of the InCharge Health Mobile App to Improve Adherence to Hydroxyurea in Patients With Sickle Cell Disease: User-Centered Design Approach. JMIR Mhealth Uhealth. 2020;8:e14884.

4. Ramsey WA. eHealth and mHealth interventions in pediatric cancer: A systematic review of interventions across the cancer continuum. Psychooncology. 2020;29:17–37.

5. Radovic A. Technology Use for Adolescent Health and Wellness. Pediatrics. 2020;145:S186–S194.

6. Mosaad YM. Clinical role of human leukocyte antigen in health and disease. J Immuno. 2015;82(4):283-306.

7. Urosevic M. Human leukocyte antigen–G and cancer immunoediting. Cancer Res. 2008;68(3):627-30.

8. Kawashima Y. Adaptation of HIV-1 to human leukocyte antigen class I. Nat. 2009;458(7238):641-5.

9. Moore GE. Culture of normal human leukocytes. Jama. 1967;199(8):519-24.

10. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Nat Cancer Inst. 1960;25(1):85-109.

Citation: *Malik J. Sensitization to human leukocyte antigens in heart transplantation. Curr Trend Cardiol 2023;7(12):233*